SAT0509 BODY MASS INDEX AND DISEASE ACTIVITY IN PORTUGUESE AND BRAZILIAN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS: RESULTS FROM RHEUMATIC DISEASES PORTUGUESE REGISTER – REUMA.PT

Objective: Since obesity has been associated with a higher inflammatory burden and worse response to therapy in patients with chronic inflammatory rheumatic diseases (CIRD), we aimed to confirm the potential association between body mass index (BMI) and disease activity in a large series of patients with CIRDs included in the Spanish CARdiovascular in rheuMAtology (CARMA) registry. Methods: Baseline data analysis of patients included from the CARMA project, a 10-year prospective study of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) attending outpatient rheumatology clinics from 67 Spanish hospitals. Obesity was defined when BMI (kg/m2) was >30 according to the WHO criteria. Scores used to evaluate disease activity were Disease Activity Score of 28 joints (DAS28) in RA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in AS, and modified DAS for PsA. Results: Data from 2234 patients (775 RA, 738 AS, and 721 PsA) were assessed. The mean ± SD BMI at the baseline visit were: 26.9 ± 4.8 in RA, 27.4 ± 4.4 in AS, and 28.2 ± 4.7 in PsA. A positive association between BMI and disease activity in patients with RA (β = 0.029; 95%CI (0.01–0.05); p = 0.007) and PsA (β = 0.036; 95%CI (0.015–0.058); p = 0.001) but not in those with AS (β = 0.001; 95%CI (−0.03–0.03); p = 0.926) was found. Disease activity was associated with female sex and rheumatoid factor in RA and with Psoriasis Area Severity Index and enthesitis in PsA. Conclusions: BMI is associated with disease activity in RA and PsA, but not in AS. Given that obesity is a potentially modifiable factor, adequate control of body weight can improve the outcome of patients with CIRD and, therefore, weight control should be included in the management strategy of these patients.

Download Full-text

Body Mass Index Impact on Disease Activity, Clinical and Sonographic Remission Rates in Patients with Rheumatoid Arthritis

Current Rheumatology Reviews ◽

10.2174/1573397115666181130143239 ◽

2019 ◽

Vol 15 (3) ◽

pp. 215-223

Author(s):

Tanya Sapundzhieva ◽

Rositsa Karalilova ◽

Anastas Batalov

Keyword(s):

Rheumatoid Arthritis ◽

Body Mass Index ◽

Disease Activity ◽

Body Mass ◽

Normal Weight ◽

Clinical Disease ◽

Clinical Disease Activity ◽

Das 28 ◽

Remission Rates ◽

Activity Indices

Aim: To investigate the impact of body mass index (BMI) on clinical disease activity indices and clinical and sonographic remission rates in patients with rheumatoid arthritis (RA). Patients and Methods: Sixty-three patients with RA were categorized according to BMI score into three groups: normal (BMI<25), overweight (BMI 25-30) and obese (BMI≥30). Thirty-three of them were treated with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), and 30 with biologic DMARDs (bDMARDs). Patients underwent clinical and laboratory assessment and musculoskeletal ultrasound examination (MSUS) at baseline and at 6 months after initiation of therapy. We evaluated the rate of clinical and sonographic remission (defined as Power Doppler score (PD) = 0) and its correlation with BMI score. Results: In the csDMARDs group, 60% of the normal weight patients reached DAS28 remission; 33.3% of the overweight; and 0% of the obese patients. In the bDMARDs group, the percentage of remission was as follows: 60% in the normal weight subgroup, 33.3% in the overweight; and 15.8% in the obese. Within the csDMARDs treatment group, two significant correlations were found: BMI score–DAS 28 at 6th month, rs = .372, p = .033; BMI score–DAS 28 categories, rs = .447, p = .014. Within the bDMARDs group, three significant correlations were identified: BMI score–PDUS at sixth month, rs = .506, p =.004; BMI score–DAS 28, rs = .511, p = .004; BMI score–DAS 28 categories, rs = .592, p = .001. Sonographic remission rates at 6 months were significantly higher in the normal BMI category in both treatment groups. Conclusion: BMI influences the treatment response, clinical disease activity indices and the rates of clinical and sonographic remission in patients with RA. Obesity and overweight are associated with lower remission rates regardless of the type of treatment.

Download Full-text

P392 Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjy222.516 ◽

2019 ◽

Vol 13 (Supplement_1) ◽

pp. S304-S304

Author(s):

K Soufleris ◽

K Fasoulas ◽

N Kafalis ◽

G Lazaraki ◽

D Tzilves

Keyword(s):

Body Mass Index ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Disease Activity ◽

Treatment Response ◽

Body Mass ◽

Moderate Disease ◽

Moderate Disease Activity

Download Full-text

277 Body mass index at time of diagnosis is predictive of future disease activity in SLE

10.1136/lupus-2019-lsm.277 ◽

2019 ◽

Author(s):

George Stojan ◽

Laurence Magder ◽

Daniel Goldman ◽

Michelle Petri

Keyword(s):

Body Mass Index ◽

Disease Activity ◽

Body Mass

Download Full-text

Increased Body Mass Index in Ankylosing Spondylitis Is Associated with Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise

The Journal of Rheumatology ◽

10.3899/jrheum.120595 ◽

2012 ◽

Vol 39 (12) ◽

pp. 2310-2314 ◽

Cited By ~ 34

Author(s):

LAURA DURCAN ◽

FIONA WILSON ◽

RICHARD CONWAY ◽

GAYE CUNNANE ◽

FINBAR D. O’SHEA

Keyword(s):

Body Mass Index ◽

Ankylosing Spondylitis ◽

Disease Activity ◽

Body Mass ◽

Functional Disability ◽

Activity Index ◽

Demographic Data ◽

Functional Limitation ◽

Disease Characteristics ◽

Significant Difference

Objective.Increased body mass index (BMI) in patients with ankylosing spondylitis (AS) is associated with a greater burden of symptoms and poor perceptions of the benefits of exercise. In AS, the effect of obesity on disease characteristics and exercise perceptions is unknown. We evaluated the prevalence of obesity in AS, to assess the attitudes of patients toward exercise and to evaluate the effect of obesity on symptoms and disease activity.Methods.Demographic data and disease characteristics were collected from 46 patients with AS. Disease activity, symptomatology, and functional disability were examined using standard AS questionnaires. BMI was calculated. Comorbidity was analyzed using the Charlson Comorbidity Index. Patients’ attitudes toward exercise were assessed using the Exercise Benefits and Barriers Scale (EBBS). We compared the disease characteristics, perceptions regarding exercise, and functional limitations in those who were overweight to those who had a normal BMI.Results.The mean BMI in the group was 27.4; 67.5% of subjects were overweight or obese. There was a statistically significant difference between those who were overweight and those with a normal BMI regarding their perceptions of exercise (EBBS 124.7 vs 136.6, respectively), functional limitation (Bath AS Functional Index 4.7 vs 2.5, Health Assessment Questionnaire 0.88 vs 0.26), and disease activity (Bath AS Disease Activity Index 4.8 vs 2.9). There was no difference between the groups in terms of their comorbid conditions or other demographic variables.Conclusion.The majority of patients in this AS cohort were overweight. They had a greater burden of symptoms, worse perceptions regarding the benefits of exercise, and enhanced awareness of their barriers to exercising. This is of particular concern in a disease where exercise plays a crucial role.

Download Full-text